115 related articles for article (PubMed ID: 19075620)
1. Transcriptome and proteome analyses of drug interactions with natural products.
Fang H; Wang K; Zhang J
Curr Drug Metab; 2008 Dec; 9(10):1038-48. PubMed ID: 19075620
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Sun X; He Y; Mao C; Zhu L; Qin X; Huang S
Leuk Lymphoma; 2014 Feb; 55(2):435-8. PubMed ID: 23772664
[No Abstract] [Full Text] [Related]
3. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
5. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.
Porosnicu M; Nimmanapalli R; Nguyen D; Worthington E; Perkins C; Bhalla KN
Leukemia; 2001 May; 15(5):772-8. PubMed ID: 11368438
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P
Haematologica; 2007 Jun; 92(6):838-41. PubMed ID: 17550858
[TBL] [Abstract][Full Text] [Related]
7. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
El Eit RM; Iskandarani AN; Saliba JL; Jabbour MN; Mahfouz RA; Bitar NM; Ayoubi HR; Zaatari GS; Mahon FX; De Thé HB; Bazarbachi AA; Nasr RR
Int J Cancer; 2014 Feb; 134(4):988-96. PubMed ID: 23934954
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
[TBL] [Abstract][Full Text] [Related]
9. Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.
Kashimura M; Ohyashiki K
Leuk Res; 2010 Aug; 34(8):e213-4. PubMed ID: 20299093
[No Abstract] [Full Text] [Related]
10. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
12. [Arsenic treatment for leukemia: new model of human cancer target treatment].
Zhao WW; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):439-40. PubMed ID: 15854545
[No Abstract] [Full Text] [Related]
13. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
14. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
15. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Visani G; Piccaluga PP; Martinelli G; Rossi M; Malagola M; Baccarani M
Haematologica; 2003 Apr; 88(4):ELT15. PubMed ID: 12681992
[No Abstract] [Full Text] [Related]
16. New drug targets genetic malfunction in chronic myeloid leukemia.
Am J Health Syst Pharm; 2001 Jul; 58(14):1282. PubMed ID: 11471471
[No Abstract] [Full Text] [Related]
17. Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
Inami M; Inokuchi K; Nakayama K; Tamura H; Shimada T; Dan K
Int J Hematol; 2003 Aug; 78(2):173-5. PubMed ID: 12953816
[No Abstract] [Full Text] [Related]
18. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies.
Topaly J; Zeller WJ; Fruehauf S
Br J Haematol; 2002 Oct; 119(1):3-14. PubMed ID: 12358898
[No Abstract] [Full Text] [Related]
20. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
